In keeping with the need to minimize social contact, almost all human subjects research activities involving face-to-face interactions are suspended until further notice.
The only exceptions are for clinical and human subjects research studies where:
- the research holds the potential for direct benefit to the subject (e.g., investigational drug, devices or surgical procedure) and the interaction is required to deliver that potential direct benefit;
- there is collection of safety data (based on clinical judgment of the importance of the visit to detect potential adverse events);
- the PI determines that an in-person visit is vital to the subject’s safety and/or well-being,
there is an Emergency Use / Compassionate Use / Humanitarian Use Devices (HUDs) of investigational drugs or devices;
- and/or the research has direct relevance to the current COVID-19 pandemic and the research cannot be conducted at another time (must be approved first by your research dean and or dean/center director, the Integrative Safety Committee and the relevant regulatory committees).
Note, as of August 1, 2020, face-to-face human subjects research where there is a lower risk of COVID-19 exposure resumed as part of Phase 2 of research ramp up upon approval from the investigator's respective Research/School Dean or Designate. Please see the research ramp up website for more information.